| scholarly article | Q13442814 |
| P50 | author | Mariano S Viapiano | Q58794840 |
| P2093 | author name string | E Antonio Chiocca | |
| Aneta Kwiatkowska | |||
| Prajna Behera | |||
| Mohan S Nandhu | |||
| P2860 | cites work | Oncolytic viruses | Q78595329 |
| Gene therapy | Q79541485 | ||
| Oncolytic measles virus strains in the treatment of gliomas | Q80490182 | ||
| The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier | Q83814322 | ||
| Cintredekin besudotox in treatment of malignant glioma | Q94700067 | ||
| Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery | Q39445443 | ||
| Embryonic stem cell differentiation: emergence of a new era in biology and medicine | Q22065783 | ||
| The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro | Q24564192 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Gene therapy for brain tumors: basic developments and clinical implementation | Q26829086 | ||
| Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy | Q27004205 | ||
| Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing | Q28131793 | ||
| Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule | Q28371265 | ||
| Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas | Q28574605 | ||
| Mammalian neural stem cells | Q29547657 | ||
| Malignant gliomas in adults | Q29615708 | ||
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
| Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma | Q30885561 | ||
| HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival | Q30954768 | ||
| A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. | Q32016260 | ||
| Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir | Q32060420 | ||
| Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors | Q33560685 | ||
| Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. | Q33638847 | ||
| Poly(ethylenimine) and its role in gene delivery | Q33698747 | ||
| Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM | Q33712977 | ||
| Adenovirus-mediated p53 gene therapy for human gliomas | Q33767734 | ||
| Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 | ||
| Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas | Q34073228 | ||
| Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells | Q34073330 | ||
| The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study | Q34124333 | ||
| Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene | Q34124630 | ||
| Gene therapy finds its niche | Q34163207 | ||
| Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model | Q34183356 | ||
| Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome | Q39448946 | ||
| The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma. | Q39466558 | ||
| Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors. | Q39531933 | ||
| A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models | Q39630653 | ||
| Irradiation Enhances the Tumor Tropism and Therapeutic Potential of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Glioma Therapy | Q39644411 | ||
| Bifunctional Conjugates Comprising β-Cyclodextrin, Polyethylenimine, and 5-Fluoro-2′- Deoxyuridine for Drug Delivery and Gene Transfer | Q39653974 | ||
| Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma | Q39664427 | ||
| Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. | Q39673421 | ||
| Bystander killing effect of tymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells | Q39673692 | ||
| Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. | Q39725116 | ||
| Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma | Q39910399 | ||
| Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats | Q39947440 | ||
| Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma | Q39990832 | ||
| Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy | Q40043828 | ||
| Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma | Q40107189 | ||
| Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma | Q40134103 | ||
| Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas | Q40171214 | ||
| Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity | Q40192848 | ||
| Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus | Q40314091 | ||
| Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models | Q40327891 | ||
| Bystander-killing effect and cyclic induction of TNF-alpha gene under heat-inducible promoter gadd 153. | Q40360669 | ||
| PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model | Q40382315 | ||
| Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas | Q40416129 | ||
| Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy | Q40438513 | ||
| Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. | Q40476541 | ||
| Application of p27 gene therapy for human malignant glioma potentiated by using mutant p27. | Q40518275 | ||
| Cell therapy using encapsulated cells producing endostatin. | Q40628334 | ||
| Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy | Q40651485 | ||
| Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors | Q40718975 | ||
| Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials | Q40790899 | ||
| Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model | Q40835797 | ||
| Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. | Q40963694 | ||
| Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene | Q41029856 | ||
| The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. | Q41517544 | ||
| Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene | Q41682923 | ||
| Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line | Q41716747 | ||
| Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism | Q41810186 | ||
| Oncolytic measles virus strains have significant antitumor activity against glioma stem cells | Q41869447 | ||
| Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity | Q42133458 | ||
| An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy | Q42542383 | ||
| A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. | Q42639115 | ||
| Potentials and limitations of adenovirus-p53 gene therapy for brain tumors | Q42679753 | ||
| Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. | Q42804628 | ||
| The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma | Q42809291 | ||
| In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors | Q42818740 | ||
| A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy | Q42833512 | ||
| The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. | Q43061941 | ||
| Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. | Q43761368 | ||
| New drug delivery system for water-soluble drugs using silicone and its usefulness for local treatment: application of GCV-silicone to GCV/HSV-tk gene therapy for brain tumor | Q43880779 | ||
| Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector | Q43890874 | ||
| Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane | Q44184290 | ||
| Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy | Q44198636 | ||
| A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. | Q52537791 | ||
| Regression of Burkitt's lymphoma in association with measles infection. | Q53987611 | ||
| Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. | Q55473726 | ||
| [Treatment of malignant glioma with mumps virus (author's transl)] | Q55489929 | ||
| TNF-α and the IFN-γ-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma | Q62019424 | ||
| A phase I trial of Ad.hIFN-beta gene therapy for glioma | Q64376835 | ||
| Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies | Q64382810 | ||
| Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy | Q70147645 | ||
| Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway | Q44432093 | ||
| Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models | Q44669457 | ||
| Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial | Q44697883 | ||
| Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. | Q44697885 | ||
| Gene therapy of experimental brain tumors using neural progenitor cells | Q44761775 | ||
| Possible effect of measles on leukaemia | Q44779558 | ||
| Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir | Q44873437 | ||
| Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status | Q45130713 | ||
| Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro | Q45149631 | ||
| Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy | Q45180665 | ||
| Liposome-mediated suicide gene therapy in humans | Q45274513 | ||
| In vivo enhancement of herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy with polyamine biosynthesis inhibition | Q45421226 | ||
| Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme | Q45723594 | ||
| A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. | Q45739549 | ||
| Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir | Q45741729 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. | Q45854952 | ||
| Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results | Q45863348 | ||
| A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma | Q45864522 | ||
| Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine | Q45864786 | ||
| Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells | Q45866586 | ||
| Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas | Q45869995 | ||
| Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas | Q45870836 | ||
| Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene | Q45871076 | ||
| In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug | Q45872110 | ||
| Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes | Q45872808 | ||
| Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model | Q45875290 | ||
| p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. | Q45877613 | ||
| Suppression of invasion in human U87 glioma cells by adenovirus-mediated co-transfer of TIMP-2 and PTEN gene | Q45877890 | ||
| Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy | Q45880329 | ||
| Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas | Q45880481 | ||
| Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir | Q45882352 | ||
| Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. | Q45888769 | ||
| In vivo tracking of neural progenitor cell migration to glioblastomas | Q48209565 | ||
| PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli | Q48319236 | ||
| Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. | Q48331127 | ||
| Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. | Q48489790 | ||
| An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor | Q48945443 | ||
| The use of neural stem cells in cancer gene therapy: predicting the path to the clinic | Q34217778 | ||
| Gene therapy for human genetic disease? | Q34227501 | ||
| Stem cells as therapeutic vehicles for the treatment of high-grade gliomas | Q34240433 | ||
| Retracted: Replication, Neurotropism, and Pathogenicity of Avian Paramyxovirus Serotypes 1-9 in Chickens and Ducks | Q34256243 | ||
| Suicide gene therapy in cancer: where do we stand now? | Q34277497 | ||
| In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy | Q34341355 | ||
| Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. | Q34359268 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Apoptosis in human glioblastoma cells produced using embryonic stem cell-derived astrocytes expressing tumor necrosis factor-related apoptosis-inducing ligand | Q34551591 | ||
| In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas | Q34803686 | ||
| Gene therapy progress and prospects: nonviral vectors. | Q35011746 | ||
| Directing systemic oncolytic viral delivery to tumors via carrier cells | Q35029126 | ||
| Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses | Q35036505 | ||
| Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives | Q35085457 | ||
| Application of magnetic nanoparticles to gene delivery | Q35091789 | ||
| Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy | Q35119552 | ||
| Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts | Q35175677 | ||
| Viral therapy for glioblastoma | Q35210466 | ||
| Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. | Q35238250 | ||
| A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma | Q35256949 | ||
| Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma | Q35610305 | ||
| Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation | Q35695799 | ||
| Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector | Q35696378 | ||
| Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment | Q35719080 | ||
| Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus | Q35750059 | ||
| Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model | Q35800497 | ||
| Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas | Q35827956 | ||
| Herpes simplex virus latency-associated transcript sequence downstream of the promoter influences type-specific reactivation and viral neurotropism | Q35857276 | ||
| Herpes simplex virus-based vectors | Q35863367 | ||
| Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors | Q35867997 | ||
| Emerging insights into the molecular and cellular basis of glioblastoma | Q35914897 | ||
| Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12 | Q35943736 | ||
| The treatment of glioblastoma multiforme through activation of microglia and TRAIL induced by rAAV2-mediated IL-12 in a syngeneic rat model | Q35968317 | ||
| From bench to bedside for gene-directed enzyme prodrug therapy of cancer | Q36061340 | ||
| Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas | Q36062517 | ||
| Dendrimers in gene delivery | Q36323319 | ||
| The art of gene therapy for glioma: a review of the challenging road to the bedside | Q36527593 | ||
| Epidemiology and molecular pathology of glioma | Q36577353 | ||
| A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery | Q36609123 | ||
| Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice | Q36634430 | ||
| Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus | Q36659325 | ||
| Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential | Q36672124 | ||
| Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice | Q36735680 | ||
| Oncolytic viruses driven by tumor-specific promoters | Q36754456 | ||
| Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma | Q36861449 | ||
| Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells | Q36909502 | ||
| Molecular pathology of malignant gliomas | Q37014747 | ||
| Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines | Q37079854 | ||
| Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo | Q37096766 | ||
| Stem and progenitor cell-mediated tumor selective gene therapy | Q37120161 | ||
| Post-translational regulation of the tumor suppressor p27(KIP1). | Q37219544 | ||
| Adenoviral virotherapy for malignant brain tumors | Q37223846 | ||
| Advances in oncolytic virus therapy for glioma | Q37287118 | ||
| Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide | Q37356520 | ||
| Gene therapy for high-grade glioma: current approaches and future directions | Q37406685 | ||
| Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas | Q37461117 | ||
| Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil | Q37756317 | ||
| Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment | Q37889662 | ||
| Investigation of varicella-zoster virus neurotropism and neurovirulence using SCID mouse-human DRG xenografts | Q37967565 | ||
| Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy | Q37989984 | ||
| Poly(amidoamine) polymers: soluble linear amphiphilic drug-delivery systems for genes, proteins and oligonucleotides | Q38029615 | ||
| The definition of primary and secondary glioblastoma | Q38064831 | ||
| Human embryonic stem cell-derived mesenchymal stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma | Q38888896 | ||
| Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma | Q39096809 | ||
| Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma | Q39199004 | ||
| Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy | Q39245228 | ||
| Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. | Q39282411 | ||
| Smart multifunctional core-shell nanospheres with drug and gene co-loaded for enhancing the therapeutic effect in a rat intracranial tumor model | Q39282791 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 1271-1305 | |
| P577 | publication date | 2013-10-23 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Strategies in gene therapy for glioblastoma | |
| P478 | volume | 5 |
| Q36155208 | Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma |
| Q30417964 | Bionanotechnology and the future of glioma |
| Q39233422 | Brain-Targeted Polymers for Gene Delivery in the Treatment of Brain Diseases |
| Q38841046 | Cancer suicide gene therapy: a patent review. |
| Q42146754 | Chondroitin sulfate-polyethylenimine copolymer-coated superparamagnetic iron oxide nanoparticles as an efficient magneto-gene carrier for microRNA-encoding plasmid DNA delivery |
| Q52571345 | Direct-Current Electric Field Distribution in the Brain for Tumor Treating Field Applications: A Simulation Study. |
| Q64094581 | Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma |
| Q40060078 | Gene Delivery in Neuro-Oncology |
| Q35673628 | Gene therapy for malignant glioma |
| Q26776219 | Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma |
| Q90618650 | Glioblastoma Treatment Modalities besides Surgery |
| Q38393328 | Glioblastoma: molecular pathways, stem cells and therapeutic targets |
| Q92745973 | MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2 |
| Q38402828 | Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions |
| Q36470507 | Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma |
| Q92344294 | Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models |
| Q26776345 | Overview of current immunotherapeutic strategies for glioma |
| Q35127438 | Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. |
| Q58117045 | Receptor-Targeted Glial Brain Tumor Therapies |
| Q40311561 | Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs |
| Q57291853 | Targeted Theranostic Nanoparticles for Brain Tumor Treatment |
| Q35176800 | Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. |
| Q36250616 | Three-dimensional assessment of bystander effects of mesenchymal stem cells carrying a cytosine deaminase gene on glioma cells |
| Q61449204 | Tracking Neural Progenitor Cell Migration in the Rodent Brain Using Magnetic Resonance Imaging |
| Q91968731 | Viral vector: potential therapeutic for glioblastoma multiforme |
Search more.